Systemic complement activation following human acute ischaemic stroke. - Wikidata - thesis-toulmin - TriplyDB

Systemic complement activation following human acute ischaemic stroke.

Systemic complement activation following human acute ischaemic stroke.

http://www.wikidata.org/entity/Q47346589

about

Complement in the Homeostatic and Ischemic Brain Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments Membrane attack by complement: the assembly and biology of terminal complement complexes On the Functional Overlap between Complement and Anti-Microbial Peptides Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage.Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'.Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury.Molecular Dissection of Cyclosporin A's Neuroprotective Effect Reveals Potential Therapeutics for Ischemic Brain Injury.The role of the immune system in central nervous system plasticity after acute injury.Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis New insights of an old defense system: structure, function, and clinical relevance of the complement system.Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume Cardioembolic and small vessel disease stroke show differences in associations between systemic C3 levels and outcome Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke Natural antibodies, autoantibodies and complement activation in tissue injury.Serum erythropoietin and outcome after ischaemic stroke: a prospective study.Predictors of systemic inflammatory response syndrome in ischemic stroke undergoing systemic thrombolysis with intravenous tissue plasminogen activator.Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?Systemic inflammatory response syndrome in tissue-type plasminogen activator-treated patients is associated with worse short-term functional outcome Immune and inflammatory responses to stroke: good or bad?Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke Complement activation: an emerging player in the pathogenesis of cardiovascular disease Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes Complement inhibition as a proposed neuroprotective strategy following cardiac arrest Injury site-specific targeting of complement inhibitors for treating stroke.CD59 efficiently protects human NT2-N neurons against complement-mediated damage.High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study).Systemic Inflammatory Response Syndrome and Outcomes in Intracerebral Hemorrhage.Serum mannose-binding lectin levels after aneurysmal subarachnoid hemorrhage.Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.IL-6 as a biomarker of ischemic cerebrovascular disease.Systemic inflammatory response syndrome, infection, and outcome in intracerebral hemorrhage.Human complement receptor type 1 (CR1) protein levels and genetic variants in chronic Chagas Disease.Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months.IL-6: an early marker for outcome in acute ischemic stroke.Complement activation and its prognostic role in post-cardiac arrest patients.

P2860

Q26796057-A8E62D75-FBFA-49D5-BDF6-C08DD7B24323 Q26800178-420773FA-83A6-4449-9592-AEF8F11FFC07 Q26997385-908DE6B4-7211-4D5B-BC5B-1ABCB79A9F76 Q28082379-1EB53970-7BCC-4724-88B7-A92F7AACBE09 Q28743387-5F6333BF-EC4D-4267-9CA3-A3C853E6C5B2 Q31132259-A6526A57-AD4A-47C5-8309-7E53F81DEA04 Q33436029-90BD944E-65AF-4B0D-9719-96EBEEA19C03 Q33530136-24427C9B-C603-4F1C-9FDB-8BBC8F755F67 Q33649734-BA4200FF-2B60-4A27-B899-EB2745E6ACA9 Q33772181-C7FCFC23-97BA-4CA1-979A-B53C7FD5060D Q34206790-BEAD1EAC-DBAF-49F6-9443-1BD7D034A906 Q34471200-2C1BBF7D-D1B7-4317-AE43-832D0E486C16 Q34699496-90E4A44B-086A-4EC3-84FD-6D803CAB9360 Q34729372-D2A7C97D-8BA2-474E-B5CE-E5DDFD644420 Q34973359-F001454F-3AA9-4738-8B5F-A902807368DB Q35857874-03AF9686-79E6-4C0B-A39C-A514FC073AFC Q36572982-8C40DE01-6489-4E7E-9F10-3CDDF90624E0 Q36625386-27C91BC7-7E49-4D9C-8052-438ABF6239AA Q36657661-F89A040D-8B9E-406A-A090-8A40BC1D6DA3 Q37091310-29925E43-3BF1-44EF-8221-3A139143C7DC Q37183514-EAC6C943-94ED-449A-A476-FECDDAFE8D4F Q37206731-43DA3F52-2E27-4D9A-B73A-59CDD82602E1 Q37277232-E3BC7587-E21B-4632-A0A2-33253BD6FD64 Q37280979-2A0DB822-0B1A-41FF-A17A-5B07B8BE917F Q37288362-BBCEF657-DD57-4532-8C6E-113629338391 Q37421961-D05FDBD1-16A1-4319-A34D-170C34541AE0 Q37691243-323BEC79-486B-41EF-B7C9-EA484F000B38 Q38991032-D4038C8C-AED0-43A2-83CC-3C79C84F6A97 Q40106379-0194C1B4-C557-420E-B64F-A91FF04E2403 Q40551608-6A4D0DF6-F88C-41C5-B059-A5F7966DF8CD Q40775597-3FBEB6B4-4FB4-44BB-A82A-9CC0DE4FC125 Q40961686-468EE42F-2544-45F4-9D3C-B7EC1C82F8B9 Q43581917-E3FBA314-640B-48E9-98E6-3E894765E339 Q43930022-371B1907-4C53-4994-B01A-1200159B05E1 Q47661525-7570338C-A1FE-4703-8912-985AC15C1A2A Q48262765-6B9AE7A0-B90E-4156-BED0-211E6C6412C3 Q48710750-BC6E40B2-9A80-444E-AEC6-0CEF53C20762 Q48899503-37EC0326-EC66-491C-B6CB-AC0F0CF643C1 Q50712609-B672F958-D93C-47B8-A8B3-72335FFC4F81

P2860

Systemic complement activation following human acute ischaemic stroke.

http://www.wikidata.org/entity/Q47346589

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Systemic complement activation following human acute ischaemic stroke.

@en

Systemic complement activation following human acute ischaemic stroke.

@nl

type

label

Systemic complement activation following human acute ischaemic stroke.

@en

Systemic complement activation following human acute ischaemic stroke.

@nl

prefLabel

Systemic complement activation following human acute ischaemic stroke.

@en

Systemic complement activation following human acute ischaemic stroke.

@nl

P1433

Q47346589-CC88A563-63C6-4172-A56C-88AF72361AEF

P1476

Q47346589-05E02A72-A083-4A71-9FCD-C285A587BB5B

P2093

Q47346589-75901B85-C48E-4916-A143-0C5723549676

Q47346589-A1E362FB-830B-4F3F-BF35-AAB18E73586C

Q47346589-A2179111-12ED-4B82-B657-BD3491829F18

Q47346589-C49F3567-01AD-4A60-B7E0-93EA409E3ACE

Q47346589-C97328B4-574C-484C-9811-2BEACF92BDE4

P2860

Q47346589-024B1509-4D8F-495E-BABD-4DAF1DE8707B

Q47346589-0529D432-3D3F-47B0-9746-60F74E0FB99F

Q47346589-0B1C3168-F9A3-4029-9B05-D8B25923671F

Q47346589-0D1F1A8E-02A2-4739-A37B-B2412E41461A

Q47346589-1508B2D5-3F6B-4395-BAFA-575A83220D75

Q47346589-16F13A31-A9C5-4A7F-A4DE-504227EAB8E4

Q47346589-191A5863-74F9-4D78-ACB5-CDB830778269

Q47346589-223DAB0B-9F28-4B04-8387-EFA3B79EC95A

Q47346589-23E546BC-3D36-4CB3-AB46-E16E701530BB

Q47346589-340C9E70-D251-4753-BA0C-DF961F2AB0F5

P304

Q47346589-F47B75CD-A133-43FA-9A69-939A946C37A9

P31

Q47346589-D9DFA82A-3A70-4DCF-9E31-AC470D2FDC9A

P356

Q47346589-FE24FEAF-C931-4966-8299-4F2A30E94F6D

P433

Q47346589-3FBE8364-34D5-4BBB-95AC-0C2943ED75DD

P478

Q47346589-D541DFA2-0C21-4D3A-B1CA-48AC2FCA8900

P577

Q47346589-CE5A0F46-629F-4EBF-BE5A-3246041B64A5

P5875

Q47346589-97116ADD-7188-4146-A16E-149D77509A40

P698

Q47346589-32D2E53A-64C4-4C5E-B0B0-D6FD05E2EEDA

P932

Q47346589-68203D42-0382-43FD-AAB7-933D5336AFB2

P356

J.1365-2249.2004.02489.X

P1433

Clinical and Experimental Immunology

P1476

Systemic complement activation following human acute ischaemic stroke.

@en

P2093

C A Vedeler

http://www.w3.org/2001/XMLSchema#string

E D Pedersen

http://www.w3.org/2001/XMLSchema#string

G Aamodt

http://www.w3.org/2001/XMLSchema#string

T E Mollnes

http://www.w3.org/2001/XMLSchema#string

U Waje-Andreassen

http://www.w3.org/2001/XMLSchema#string

P2860

C-reactive protein: a critical update

Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and epidemiology?

The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection

Human C-reactive protein: expression, structure, and function.

Role of the complement system in ischaemic heart disease: potential for pharmacological intervention.

Overview: pro-inflammatory cytokines in cerebrovascular ischemia.

Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement.

Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke.

Pharmacological possibilities for protection against myocardial reperfusion injury.

Complement in central nervous system inflammation.

P304

117-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2249.2004.02489.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8511849

http://www.w3.org/2001/XMLSchema#string

P698

15196251

http://www.w3.org/2001/XMLSchema#string

P932

1809093

http://www.w3.org/2001/XMLSchema#string